Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 40.65%
Tectonic Therapeutic, Inc.’s TECX share price has dipped by 40.65%, which has investors questioning if this is right time to buy.
Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate,
Tectonic Therapeutic stock soars on positive trial data
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF).
Tectonic Therapeutics’ (TECX) Stock Rockets: What’s Behind the Surge?
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its lead product candidate,
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with
Tectonic jumps on positive data from early-stage trial for lead asset
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Shares hit their 52-week high of $58.62 earlier in the session, and are now up 303% in the past 12 months. The biotechnology company said the interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with group 2 pulmonary hypertension in heart failure with preserved ejection fraction.
Tectonic Therapeutic (NASDAQ:TECX) Trading 6.7% Higher Following Analyst Upgrade
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report)’s share price traded up 6.7% on Friday after Wells Fargo & Company raised their price target on the stock from $79.00 to $112.00. Wells Fargo & ...
BioWorld2d
Wall Street relaxin as Tectonic plates up phase Ib heart data
Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...
Eli Lilly trial update on kidney drug hurts Tectonic
Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental ...
Optimistic Outlook for Tectonic Therapeutic’s TX45: A Promising Candidate for Unmet Medical Needs
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...